insights_auto
Why is DRREDDY down 2.51%?
Dive Deeperchevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹ 1,202.00
arrow_downward
-2.51%(-31.00) 1D
10-р сарын 1, 15:30:00 (GMT+5:30) · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
₹ 1,233.00
High
₹ 1,233.90
Low
₹ 1,194.90
Mkt. cap
1.00ИН
Avg. vol.
1.67 сая
Volume
2.61 сая
Dividend
0.67%
Quarterly dividend
₹ 2.00
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.08
52-wk high
₹ 1,414.90
52-wk low
₹ 1,101.00
EPS
₹ 38.67
Shares outstanding
166.06 сая
No. of employees
28 мян
Open
₹ 1,233.00
High
₹ 1,233.90
Low
₹ 1,194.90
Mkt. cap
1.00ИН
Avg. vol.
1.67 сая
Volume
2.61 сая
Dividend
0.67%
Quarterly dividend
₹ 2.00
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.08
52-wk high
₹ 1,414.90
52-wk low
₹ 1,101.00
EPS
₹ 38.67
Shares outstanding
166.06 сая
No. of employees
28 мян
News stories
From web sources and news partners
MarketBeat
·
11 минутын өмнө
Simmons First National (NASDAQ:SFNC) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?
Simply Wall Street
·
46 минутын өмнө
Will Product Recalls Change ICU Medical (ICUI) Stock Narrative
Cryptonews.net
·
55 минутын өмнө
XRP to $2? Analyzing How Nasdaq Listing Could Impact Token Price
Yahoo Finance
·
2 цагийн өмнө
BillionToOne (NasdaqGS:BLLN) Stock Fair Value Edges Higher As Analysts Weigh Tech And Reimbursement Risk
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5 мян
Founded1984
HeadquartersХайдерабад, Андрапрадеш, Энэтхэг
SectorPharmaceutical industry
Websitedrreddys.com